148 related articles for article (PubMed ID: 27469031)
1. Validation of a multi-omics strategy for prioritizing personalized candidate driver genes.
Liang L; Song L; Yang Y; Tian L; Li X; Wu S; Huang W; Ren H; Tang N; Ding K
Oncotarget; 2016 Jun; 7(25):38440-38450. PubMed ID: 27469031
[TBL] [Abstract][Full Text] [Related]
2. Leveraging a Multi-Omics Strategy for Prioritizing Personalized Candidate Mutation-Driver Genes: A Proof-of-Concept Study.
Ding K; Wu S; Ying W; Pan Q; Li X; Zhao D; Li X; Zhao Q; Zhu Y; Ren H; Qian X
Sci Rep; 2015 Dec; 5():17564. PubMed ID: 26631547
[TBL] [Abstract][Full Text] [Related]
3. HNF1A POU Domain Mutations Found in Japanese Liver Cancer Patients Cause Downregulation of
Haque E; Teeli AS; Winiarczyk D; Taguchi M; Sakuraba S; Kono H; Leszczyński P; Pierzchała M; Taniguchi H
Genes (Basel); 2022 Feb; 13(3):. PubMed ID: 35327967
[TBL] [Abstract][Full Text] [Related]
4. [Mutations of tumor suppressor gene PTEN mutations in hepatocellular carcinoma and its implications in tumor proliferation and apoptosis].
Guo SP; Wang L; Wang WL; Li QL; Wang WY; Zhang J
Zhonghua Bing Li Xue Za Zhi; 2006 Aug; 35(8):467-72. PubMed ID: 17069699
[TBL] [Abstract][Full Text] [Related]
5. Discovering personalized driver mutation profiles of single samples in cancer by network control strategy.
Guo WF; Zhang SW; Liu LL; Liu F; Shi QQ; Zhang L; Tang Y; Zeng T; Chen L
Bioinformatics; 2018 Jun; 34(11):1893-1903. PubMed ID: 29329368
[TBL] [Abstract][Full Text] [Related]
6. Hepatocellular carcinoma as extracolonic manifestation of Lynch syndrome indicates SEC63 as potential target gene in hepatocarcinogenesis.
Casper M; Weber SN; Kloor M; Müllenbach R; Grobholz R; Lammert F; Zimmer V
Scand J Gastroenterol; 2013 Mar; 48(3):344-51. PubMed ID: 23537056
[TBL] [Abstract][Full Text] [Related]
7. C/EBPα inhibits hepatocellular carcinoma by reducing Notch3/Hes1/p27 cascades.
Shi YC; Zhao H; Yin C; Zeng X; Zhang Q; Xu WP; Wei J; Chen F; Xie WF
Dig Liver Dis; 2013 Oct; 45(10):844-51. PubMed ID: 23816696
[TBL] [Abstract][Full Text] [Related]
8. A Significant Regulatory Mutation Burden at a High-Affinity Position of the CTCF Motif in Gastrointestinal Cancers.
Umer HM; Cavalli M; Dabrowski MJ; Diamanti K; Kruczyk M; Pan G; Komorowski J; Wadelius C
Hum Mutat; 2016 Sep; 37(9):904-13. PubMed ID: 27174533
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations.
Ladeiro Y; Couchy G; Balabaud C; Bioulac-Sage P; Pelletier L; Rebouissou S; Zucman-Rossi J
Hepatology; 2008 Jun; 47(6):1955-63. PubMed ID: 18433021
[TBL] [Abstract][Full Text] [Related]
10. Gene-expression Analysis Identifies Specific Patterns of Dysregulated Molecular Pathways and Genetic Subgroups of Human Hepatocellular Carcinoma.
Hass HG; Vogel U; Scheurlen M; Jobst J
Anticancer Res; 2016 Oct; 36(10):5087-5095. PubMed ID: 27798868
[TBL] [Abstract][Full Text] [Related]
11. Inhibition mechanism of a newly cloned candidate tumor suppressor gene JST during hepatocarcinogenesis and its abnormal expression in human hepatocellular carcinoma from Qidong liver cancer risk area, China.
Dong-Dong L; Xi-Ran Z
Hepatogastroenterology; 2004; 51(56):515-25. PubMed ID: 15086194
[TBL] [Abstract][Full Text] [Related]
12. Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma.
Ding SL; Yang ZW; Wang J; Zhang XL; Chen XM; Lu FM
World J Gastroenterol; 2015 May; 21(20):6317-28. PubMed ID: 26034368
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-520e suppresses growth of hepatoma cells by targeting the NF-κB-inducing kinase (NIK).
Zhang S; Shan C; Kong G; Du Y; Ye L; Zhang X
Oncogene; 2012 Aug; 31(31):3607-20. PubMed ID: 22105365
[TBL] [Abstract][Full Text] [Related]
14. Genetic alterations in hepatocellular carcinoma: An update.
Niu ZS; Niu XJ; Wang WH
World J Gastroenterol; 2016 Nov; 22(41):9069-9095. PubMed ID: 27895396
[TBL] [Abstract][Full Text] [Related]
15. An Efficient and Easy-to-Use Network-Based Integrative Method of Multi-Omics Data for Cancer Genes Discovery.
Wei T; Fa B; Luo C; Johnston L; Zhang Y; Yu Z
Front Genet; 2020; 11():613033. PubMed ID: 33488678
[TBL] [Abstract][Full Text] [Related]
16. An individualized prognostic signature and multi‑omics distinction for early stage hepatocellular carcinoma patients with surgical resection.
Ao L; Song X; Li X; Tong M; Guo Y; Li J; Li H; Cai H; Li M; Guan Q; Yan H; Guo Z
Oncotarget; 2016 Apr; 7(17):24097-110. PubMed ID: 27006471
[TBL] [Abstract][Full Text] [Related]
17. The mutational landscape of hepatocellular carcinoma.
Lee JS
Clin Mol Hepatol; 2015 Sep; 21(3):220-9. PubMed ID: 26523267
[TBL] [Abstract][Full Text] [Related]
18. Trans-splicing repair of mutant p53 suppresses the growth of hepatocellular carcinoma cells in vitro and in vivo.
He X; Liu F; Yan J; Zhang Y; Yan J; Shang H; Dou Q; Zhao Q; Song Y
Sci Rep; 2015 Mar; 5():8705. PubMed ID: 25732051
[TBL] [Abstract][Full Text] [Related]
19. TMEM88, CCL14 and CLEC3B as prognostic biomarkers for prognosis and palindromia of human hepatocellular carcinoma.
Zhang X; Wan JX; Ke ZP; Wang F; Chai HX; Liu JQ
Tumour Biol; 2017 Jul; 39(7):1010428317708900. PubMed ID: 28718365
[TBL] [Abstract][Full Text] [Related]
20. Genetic characterization of fas-associated phosphatase-1 as a putative tumor suppressor gene on chromosome 4q21.3 in hepatocellular carcinoma.
Yeh SH; Wu DC; Tsai CY; Kuo TJ; Yu WC; Chang YS; Chen CL; Chang CF; Chen DS; Chen PJ
Clin Cancer Res; 2006 Feb; 12(4):1097-108. PubMed ID: 16489062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
